GB0326546D0 - Inhibitor imaging agents - Google Patents

Inhibitor imaging agents

Info

Publication number
GB0326546D0
GB0326546D0 GBGB0326546.9A GB0326546A GB0326546D0 GB 0326546 D0 GB0326546 D0 GB 0326546D0 GB 0326546 A GB0326546 A GB 0326546A GB 0326546 D0 GB0326546 D0 GB 0326546D0
Authority
GB
United Kingdom
Prior art keywords
imaging agents
imaging
inhibitor
inhibitor imaging
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0326546.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Amersham PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham PLC filed Critical Amersham PLC
Priority to GBGB0326546.9A priority Critical patent/GB0326546D0/en
Publication of GB0326546D0 publication Critical patent/GB0326546D0/en
Priority to BRPI0416528-4A priority patent/BRPI0416528A/pt
Priority to US10/560,371 priority patent/US20070104644A1/en
Priority to PCT/GB2004/004792 priority patent/WO2005049005A1/en
Priority to KR1020067009293A priority patent/KR20060118479A/ko
Priority to AT04798512T priority patent/ATE384519T1/de
Priority to ES04798512T priority patent/ES2299884T3/es
Priority to CA002545267A priority patent/CA2545267A1/en
Priority to JP2006538954A priority patent/JP5043438B2/ja
Priority to MXPA06005355A priority patent/MXPA06005355A/es
Priority to RU2006117298/15A priority patent/RU2006117298A/ru
Priority to EP04798512A priority patent/EP1682113B1/en
Priority to DE602004011553T priority patent/DE602004011553T2/de
Priority to AU2004290950A priority patent/AU2004290950A1/en
Priority to CNA2004800403628A priority patent/CN1901894A/zh
Priority to NO20062118A priority patent/NO20062118L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
GBGB0326546.9A 2003-11-14 2003-11-14 Inhibitor imaging agents Ceased GB0326546D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents
CNA2004800403628A CN1901894A (zh) 2003-11-14 2004-11-12 抑制剂成像剂
ES04798512T ES2299884T3 (es) 2003-11-14 2004-11-12 Agentes de formacion de imagenes.
JP2006538954A JP5043438B2 (ja) 2003-11-14 2004-11-12 阻害剤造影剤
PCT/GB2004/004792 WO2005049005A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents
KR1020067009293A KR20060118479A (ko) 2003-11-14 2004-11-12 억제제 영상화 시약
AT04798512T ATE384519T1 (de) 2003-11-14 2004-11-12 Hemmer-darstellende mittel
BRPI0416528-4A BRPI0416528A (pt) 2003-11-14 2004-11-12 agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
CA002545267A CA2545267A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents
US10/560,371 US20070104644A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents
MXPA06005355A MXPA06005355A (es) 2003-11-14 2004-11-12 Agentes inhibidores formadores de imagen.
RU2006117298/15A RU2006117298A (ru) 2003-11-14 2004-11-12 Визуализирующие агенты на основе ингибитора
EP04798512A EP1682113B1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents
DE602004011553T DE602004011553T2 (de) 2003-11-14 2004-11-12 Hemmer-darstellende mittel
AU2004290950A AU2004290950A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents
NO20062118A NO20062118L (no) 2003-11-14 2006-05-11 Inhibitor kontrastmidler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
GB0326546D0 true GB0326546D0 (en) 2003-12-17

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0326546.9A Ceased GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents

Country Status (16)

Country Link
US (1) US20070104644A1 (enExample)
EP (1) EP1682113B1 (enExample)
JP (1) JP5043438B2 (enExample)
KR (1) KR20060118479A (enExample)
CN (1) CN1901894A (enExample)
AT (1) ATE384519T1 (enExample)
AU (1) AU2004290950A1 (enExample)
BR (1) BRPI0416528A (enExample)
CA (1) CA2545267A1 (enExample)
DE (1) DE602004011553T2 (enExample)
ES (1) ES2299884T3 (enExample)
GB (1) GB0326546D0 (enExample)
MX (1) MXPA06005355A (enExample)
NO (1) NO20062118L (enExample)
RU (1) RU2006117298A (enExample)
WO (1) WO2005049005A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
ES2357861T3 (es) 2006-02-15 2011-05-03 Ge Healthcare As Agentes de contraste.
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
MX2008012387A (es) * 2006-03-29 2008-10-09 Novartis Ag Inhibidores selectivos de mmp basados en hidroxamato.
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース６−リン酸受容体を標的とする化合物
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0895988T3 (da) * 1997-08-08 2002-09-09 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
PL338633A1 (en) * 1997-08-08 2000-11-06 Pfizer Prod Inc Derivatives of aryloxyarylsuphonylamino hydroxamic acid
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
ES2220004T3 (es) * 1998-04-10 2004-12-01 Pfizer Products Inc. Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico.
ATE260251T1 (de) * 1999-08-18 2004-03-15 Warner Lambert Co Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1309579B1 (en) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibitors of matrix metalloproteinases
CA2514885A1 (en) * 2003-02-10 2004-08-19 Ge Healthcare Limited Diagnostic imaging agents with mmp inhibitory activity

Also Published As

Publication number Publication date
KR20060118479A (ko) 2006-11-23
BRPI0416528A (pt) 2007-01-09
US20070104644A1 (en) 2007-05-10
CN1901894A (zh) 2007-01-24
JP5043438B2 (ja) 2012-10-10
DE602004011553T2 (de) 2009-03-26
RU2006117298A (ru) 2007-12-20
DE602004011553D1 (de) 2008-03-13
JP2007511494A (ja) 2007-05-10
EP1682113B1 (en) 2008-01-23
AU2004290950A1 (en) 2005-06-02
ATE384519T1 (de) 2008-02-15
MXPA06005355A (es) 2006-07-10
EP1682113A1 (en) 2006-07-26
WO2005049005A1 (en) 2005-06-02
NO20062118L (no) 2006-05-11
CA2545267A1 (en) 2005-06-02
ES2299884T3 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
GB0326546D0 (en) Inhibitor imaging agents
NO20072120L (no) Enzyme Inhibitor Imaging Agents
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL180896A0 (en) Method of tumour imaging
BRPI0603177A (pt) método e prendedor para cirurgia de redução gástrica
EP1336103A4 (en) DIAGNOSIS FOR THE PRENATAL DIAGNOSIS OF SPRING BIRTHS, FUSION INFECTIONS AND FATTILLAGE DAMAGES AND DIAGNOSIS KIT THEREWITH
WO2007067920A3 (en) Imaging method, device and system
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE60207288D1 (de) Gewebespezifische fluoreszierende chelate
GB0130305D0 (en) Compounds for imaging alzheimers disease
ATE425770T1 (de) Kontrastmittel
DK1147420T3 (da) Urintrypsininhibitor til diagnosticering af AIDS
PL1604211T3 (pl) Identyfikowanie związków terapeutycznych
ITMI20011706A0 (it) Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic
FR2845267B1 (fr) Kit cutane de diagnostic de l'atopie
IL159479A (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2004082626A3 (en) Aromatase inhibitor diagnosis and therapy
ATE337020T1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen
AU2003235113A1 (en) Method of measuring neprilysin activity
GB0606985D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)